CD28 and neoplasm: Drent et al. [50] discovered that when CD28 and 4-1BB co-stimulation are combined with very low-affinity scFv, the CAR T cells exhibit improved clinical potential, superior proliferative capacity, preservation of a central memory phenotype, and significantly improved in vivo anti-tumor function while retaining their ability to discriminate target antigen density.